Clinical trial
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
NCT00306384 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00306384 |
|---|---|
| Title | Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus |
| Official title | A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Alogliptin |
| Enrollment | 3,323 |
| Start date | Mar 1, 2006 |
| Primary completion | Nov 1, 2011 |
| Completion | Nov 1, 2011 |
| First posted | Mar 23, 2006 |
| Last update posted | Mar 22, 2013 |
| Countries | Argentina, Brazil, Chile, Czechia, Dominican Republic, Germany, Guatemala, Netherlands, Peru, Poland, South Africa, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: